

The Medical Letter[®]

on Drugs and Therapeutics

Volume 66

May 13, 2024

ISSUE No.
1702

IN THIS ISSUE

COVID-19 Update: An EUA for Pevibart (*Pemgarda*) for Pre-Exposure Prophylaxisp 79

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 66 (Issue 1702)

May 13, 2024

Take CME Exams

COVID-19 UPDATE

An EUA for Pemivibart (*Pemgarda*) for Pre-Exposure Prophylaxis

The FDA has issued an Emergency Use Authorization (EUA) for the long-acting investigational IV monoclonal antibody pemivibart (*Pemgarda* – Invivyd) for pre-exposure prophylaxis of COVID-19 in persons ≥ 12 years old (weight ≥ 40 kg) who have moderate to severe immune compromise and are unlikely to respond adequately to COVID-19 vaccination (see Table 1).¹ *Pemgarda* is the only drug that is currently authorized in the US for pre-exposure prophylaxis of COVID-19. Tixagevimab/cilgavimab (*Evusheld*) was previously available under an EUA for this indication, but it lacks activity against currently circulating SARS-CoV-2 variants.²

THE NEW PRODUCT – Pemivibart is a human IgG1 monoclonal antibody derived from adintrevimab, an investigational antibody that was effective against the Delta variant of SARS-CoV-2, but not against circulating Omicron variants.³ Unlike adintrevimab, pemivibart has activity against the currently dominant JN.1 Omicron lineage of SARS-CoV-2.⁴ Pemivibart is catabolized slowly (median half-life 44.8 days).⁵

CLINICAL STUDIES – No clinical efficacy data were required for authorization of pemivibart. Issuance of the EUA was based on the results of an unpublished immunobridging trial (CANOPY Cohort A; summarized in the FDA Fact Sheet) in 306 adults with moderate to severe immune compromise. Titer levels of anti-SARS-CoV-2 JN.1 neutralizing antibodies 28 days after administration of one dose of pemivibart were compared to extrapolated titer levels of anti-SARS-CoV-2 B.1.617.2 (Delta) neutralizing antibodies 28 days after administration of a single adintrevimab dose in historical controls.

Results from the trial were mixed; antibody levels with pemivibart met the prespecified criteria for immunobridging when an authentic virus neutralization assay was used, but not when a pseudotyped virus-like particle neutralization assay

Table 1. Some Immunocompromising Conditions¹

- ▶ Moderate or severe primary immunodeficiency
- ▶ Advanced or untreated HIV infection
- ▶ Active treatment for a solid-tumor or hematologic malignancy
- ▶ Hematologic malignancy associated with poor vaccine response (e.g., acute leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma)
- ▶ Use of immunosuppressive therapy after a solid-organ or islet transplant
- ▶ Receipt of CAR T-cell therapy or hematopoietic stem cell transplant within previous 2 years
- ▶ Active treatment with other immunosuppressive or immunomodulatory drugs, such as high-dose corticosteroids (≥ 20 mg/day of prednisone or equivalent for ≥ 2 weeks) and tumor necrosis factor (TNF) inhibitors

1. FDA. Fact sheet for healthcare providers: Emergency Use Authorization for Pemgarda (pemivibart). March 2024. Available at: <https://bit.ly/3Q3K5AL>. Accessed April 25, 2024.

was used. A supplementary analysis found the immunogenicity of pemivibart against the JN.1 variant to be consistent with the immunogenicity of other antibodies against SARS-CoV-2 variants that they successfully targeted.⁵

ADVERSE EFFECTS – A hypersensitivity or infusion-related reaction occurred in 9% of patients in CANOPY Cohort A. Anaphylaxis occurred in 0.6% of 623 patients who received pemivibart in clinical trials. Pemivibart contains polysorbate 80, which is similar in structure to polyethylene glycol and has been associated with hypersensitivity reactions to COVID-19 vaccines; an immunology consult should be considered before use in patients who had a severe hypersensitivity reaction to a COVID-19 vaccine.

Influenza-like illness, fatigue, headache, and nausea have also occurred with use of pemivibart.⁵

DOSAGE AND ADMINISTRATION – The recommended dosage of *Pemgarda* is 4500 mg infused intravenously over at least 60 minutes. Patients should be monitored during and for at least 2 hours after the infusion. Additional doses can be given every 3 months. Pemivibart should not be used for post-exposure prophylaxis or treatment of COVID-19, within 2 weeks after administration of a COVID-19 vaccine, or as a substitute for vaccination.⁵ ■

1. FDA News Release. FDA roundup: March 22, 2024. Available at: <https://bit.ly/3xEwjhA>. Accessed April 25, 2024.
2. COVID-19 update: Evusheld unlikely to neutralize XBB.1.5 omicron variant. *Med Lett Drugs Ther* 2023; 65:e25.
3. MG Ison et al. Prevention of COVID-19 following a single intramuscular administration of adintrevimab: results from a phase 2/3 randomized, double-blind, placebo-controlled trial (EVADE). *Open Forum Infect Dis* 2023; 10:ofad314.
4. CDC. COVID data tracker. Variant proportions. April 13, 2024. Available at: <https://bit.ly/3Ka3HhH>. Accessed April 25, 2024.
5. FDA. Fact sheet for healthcare providers: Emergency Use Authorization of Pemgarda (pemivibart). March 2024. Available at: <https://bit.ly/3Q3K5AL>. Accessed April 25, 2024.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.